Cargando…
Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting
BACKGROUND: We evaluate the cost-effectiveness of the ‘Best Care’ integrated disease management (IDM) program for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease (COPD) compared to usual care (UC) within a primary care setting from the perspective of a publicly fun...
Autores principales: | Scarffe, Andrew D., Licskai, Christopher J., Ferrone, Madonna, Brand, Kevin, Thavorn, Kednapa, Coyle, Doug |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373353/ https://www.ncbi.nlm.nih.gov/pubmed/35962399 http://dx.doi.org/10.1186/s12962-022-00377-w |
Ejemplares similares
-
Integrated Disease Management for Chronic Obstructive Pulmonary Disease in Primary Care, from the Controlled Trial to Clinical Program: A Cohort Study
por: Hussey, Anna J, et al.
Publicado: (2021) -
Evaluating the implementation of a chronic obstructive pulmonary disease management program using the Consolidated Framework for Implementation Research: a case study
por: Paciocco, Stefan, et al.
Publicado: (2021) -
The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada
por: Black, Cody D., et al.
Publicado: (2019) -
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer
por: Kimpton, Miriam, et al.
Publicado: (2021) -
Common exacerbation-prone phenotypes across asthma and chronic obstructive pulmonary disease (COPD)
por: Hyodo, Kentaro, et al.
Publicado: (2022)